Publications by authors named "Matthew D Galsky"

Claim this Profile
C
Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer.
Reuben Ben-David, Ahmed Eraky, Brenda Hug, Matthew D Galsky, Che-Kai Tsao

BJU Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment.
Sujit S Nair, Dimple Chakravarty, Sreekumar Balan, Alexander Hakansson, Manuel Duval, Matthew D Galsky

Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Andrea Necchi, Matthew D Galsky, Nazli Dizman, David H Aggen, Neeraj Agarwal

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
Joshua J Meeks, Michiel S van der Heijden, Thomas Powles, Matthew D Galsky, Hikmat Al-Ahmadie

J Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
Matthew D Galsky, Michiel S van der Heijden, Thomas Powles, Melanie Claps, Mauricio Burotto

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials.
Alexander B Karol, Rodrigo Paredes, Anna Argulian, Himanshu Joshi, Lexi Weintraub, Matthew D Galsky

Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation.
Sia V Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew D Galsky, Thomas Powles

Nat Rev Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.
Jonathan F Anker, Menggang Yu, Matthew D Galsky

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.
Thomas B Powles, Enrique Grande, Nimira Alimohamed, Niara Oliveira, Srikala S Sridhar, Matthew D Galsky

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscle-Invasive Bladder Cancer: A Watershed Moment.
Matthew D Galsky, Leslie Ballas, Ashish M Kamat

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.
Matthew D Galsky, Dean F Bajorin, Yoshihiko Tomita, Dingwei Ye, Mads Agerbaek

Nat Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
Susan Halabi, Siyuan Guo, Bin Luo, Chenxi Yu, Todd P Knutson, Matthew D Galsky

Eur Urol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 and urothelial carcinoma: current understanding and future directions.
Daniele Raggi, Emanuele Crupi, Filippo Pederzoli, Alberto Martini, Alberto Briganti, Matthew D Galsky

Nat Rev Urol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer.
Vaibhav G Patel, Deepak K Singh, Himanshu Joshi, Nyima Sherpa, Bobby Liaw, Matthew D Galsky

medRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.
Saad O Atiq, Matthew D Galsky

Eur Urol Focus· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial.
Mansi Saxena, Jonathan F Anker, Julia Kodysh, Timothy O'Donnell, Anna M Kaminska, Matthew D Galsky

Nat Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.
Shilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, Jens Bedke, Begoña P Valderrama, Matthew D Galsky

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of HER2-targeted therapy in urothelial carcinomas.
Jeanny B Aragon-Ching, Matthew D Galsky

Expert Opin Emerg Drugs· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.
Mansi Saxena, Thomas U Marron, Julia Kodysh, John P Finnigan, Sayali Onkar, Matthew D Galsky

Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.
Matthew D Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen, Xiangnan Guan

Cancer Immunol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
Matthew D Galsky, Karen A Autio, Christopher R Cabanski, Kristopher Wentzel, Julie N Graff

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma.
Eric J Miller, Matthew D Galsky

Expert Rev Anticancer Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Durvalumab in Bladder Cancer. Reply.
Thomas Powles, Matthew D Galsky, Michiel S van der Heijden

N Engl J Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis